Curcumin (with Piperine/Liposomal) vs Dasatinib + Quercetin (Senolytic Stack)

Mechanism

Curcumin modulates over 100 molecular targets. Primary mechanisms include direct inhibition of NF-kB nuclear translocation (master inflammatory transcription factor), suppression of COX-2 and iNOS expression, inhibition of STAT3 and AP-1 signaling, and activation of Nrf2-ARE pathway upregulating Phase II detoxification enzymes (glutathione S-transferase, heme oxygenase-1). It also inhibits mTOR signaling and modulates epigenetic enzymes (HATs, HDACs, DNMTs).

Standard Dosing

500-1000mg curcuminoids daily (enhanced bioavailability form)

Timing

With meals containing fat. Piperine enhances absorption 2000% but also affects drug metabolism.

Cycle Duration

ongoing

Side Effects

• GI upset/diarrhea at high doses
• Yellow staining of teeth/skin
• Rare: contact dermatitis
• Potential iron depletion with chronic high-dose use

Contraindications

• Gallbladder obstruction/gallstones (stimulates bile flow)
• Iron-deficiency anemia (chelates iron)
• Scheduled surgery (discontinue 2 weeks prior)
• Pregnancy at therapeutic doses

Best Stacking Partners

Mechanism

Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.

Standard Dosing

Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).

Timing

Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.

Cycle Duration

Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).

Side Effects

• GI discomfort, nausea, diarrhea (both compounds)
• Fluid retention and peripheral edema (dasatinib)
• Headache
• Thrombocytopenia and neutropenia (dasatinib — typically mild at senolytic doses)
• Pleural effusion (rare at intermittent dosing; more common with chronic oncology dosing)
• Skin rash

Contraindications

• Active bleeding disorders or thrombocytopenia
• Severe hepatic impairment
• Pulmonary arterial hypertension
• QT prolongation risk or concurrent QT-prolonging drugs
• Pregnancy and breastfeeding
• Active infections (temporary immunosuppression)

Best Stacking Partners